Celldex Therapeutics reported encouraging Phase 2 results for barzolvolimab, a monoclonal antibody targeting mast cells, across multiple urticaria indications at the American Academy of Allergy, Asthma & Immunology annual meeting. The company's data demonstrated that 71% of chronic spontaneous urticaria (CSU) patients achieved complete response following 52 weeks of treatment, with half of these responders maintaining complete response seven months after discontinuing therapy. The sustained off-treatment efficacy represents a notable clinical outcome for the investigational therapy.
Beyond CSU, Celldex presented additional Phase 2 findings showing improved disease control and quality-of-life measures in patients with cold urticaria and symptomatic dermographism. These broader clinical benefits across the urticaria spectrum underscore the potential therapeutic scope of the mast cell-targeting approach. The company characterized barzolvolimab as a first-in-class and best-in-disease candidate, positioning it within the competitive landscape of urticaria treatments.
Celldex has accelerated its Phase 3 CSU development program, completing enrollment six months ahead of the original timeline. The company anticipates topline Phase 3 data in the fourth quarter of 2026, marking a significant near-term catalyst for the program's advancement toward potential regulatory submission.